IL6 and rheumatoid arthritis: Interestingly, in a post hoc analysis of RA-BEGIN and RA-BEAM, reduced structural progression (mTSS) was observed regardless of disease activity control (Clinical Disease Activity Index [CDAI] REM and LDA versus CDAI moderate and high disease activity) in baricitinib-treated patients, but not in those who received placebo or MTX [43], providing evidence of an uncoupling of the link between disease activity and radiographic progression previously demonstrated with TNFis, IL-6 inhibitors and rituximab [44,45,46].